ArticleAntibiotics (Basel, Switzerland)2022
Emergence of Fosfomycin Resistance by Plasmid-Mediated
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- UropathogenicAntibiotics (Basel, Switzerland) · 2026Review
- Phenotypic Fosfomycin Susceptibility and Detection of Plasmid-Mediated Resistance Genes in Clinical UropathogenicMicroorganisms · 2026Article
- Emergence of Fosfomycin Resistance Among ESBL-ProducingHealth science reports · 2026Article
- Expanding Threat of Carbapenemase-ProducingbioRxiv : the preprint server for biology · 2026Article
- Mechanisms of fosfomycin resistance observed in clinical isolates ofJAC-antimicrobial resistance · 2026Article
- Intestinal and Extraintestinal Pathotypes ofAntibiotics (Basel, Switzerland) · 2025Article
- Fosfomycin-resistantJAC-antimicrobial resistance · 2025Article
- Article
- Salmonella isolated from street foods and environment of an urban park: A whole genome sequencing approach.PloS one · 2025Article
- Drug susceptibility of uropathogens isolated from patients treated at the Mazovian Specialized Hospital in Radom.Acta biochimica Polonica · 2025Article
- Overcoming the drug resistance barrier: progress in fosfomycin combination therapy against multidrug-resistant pathogens.Frontiers in microbiology · 2025Review
- A review of the mechanisms that confer antibiotic resistance in pathotypes ofFrontiers in cellular and infection microbiology · 2024Review
- UropathogenicMicroorganisms · 2023Review
- Fosfomycin resistance mechanisms inFrontiers in cellular and infection microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 15 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fosfomycin is currently a viable option against urinary tract infections, particularly against extended-spectrum β-lactamases (ESBL)-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.